2017
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Krop I, Ismaila N, Andre F, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Mennel RG, Van Poznak C, Wolff AC, Stearns V. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal Of Clinical Oncology 2017, 35: jco.2017.74.047. PMID: 28692382, PMCID: PMC5846188, DOI: 10.1200/jco.2017.74.0472.Peer-Reviewed Original ResearchConceptsAdjuvant systemic therapyNode-positive breast cancerAdjuvant systemic chemotherapyHigh clinical riskBreast cancerSystemic therapyClinical riskSystemic chemotherapySuch patientsClinical utilityEarly-stage invasive breast cancerClinical Oncology Clinical Practice GuidelineNode-negative breast cancerOncology Clinical Practice GuidelineHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Triple-negative breast cancerGood-prognosis populationUse of MammaPrintInvolved lymph nodesGrowth factor receptor 2Invasive breast cancerClinical practice guidelinesClinical risk categories
2014
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline
Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Gonzalez-Angulo AM, Kirshner JJ, Krop I, Levinson J, Modi S, Patt DA, Perez EA, Perlmutter J, Winer EP, Lin NU. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: American Society of Clinical Oncology Clinical Practice Guideline. Journal Of Clinical Oncology 2014, 32: 2100-2108. PMID: 24799487, PMCID: PMC6366342, DOI: 10.1200/jco.2013.54.0955.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBrain NeoplasmsBreast NeoplasmsComorbidityConsensusCranial IrradiationDisease ManagementEvidence-Based MedicineFemaleHealth Status DisparitiesHealthcare DisparitiesHumansRadiosurgeryReceptor, ErbB-2Societies, MedicalTreatment OutcomeUnited StatesConceptsMagnetic resonance imagingHuman epidermal growth factor receptorAdvanced breast cancerBrain metastasesBreast cancerEpidermal growth factor receptorGrowth factor receptorSystemic therapyLocal therapyAdvanced human epidermal growth factor receptorHER2-positive advanced breast cancerClinical Oncology Clinical Practice GuidelineExpert consensus-based recommendationsOncology Clinical Practice GuidelineConsensus-based processRoutine magnetic resonance imagingAppropriate local therapyBest supportive careWhole brain radiotherapySize of metastasesFactor receptorClinical practice guidelinesPresence of symptomsConsensus-based recommendationsAmerican Society